Learn what retatrutide is, how this next‑generation triple agonist (GLP‑1, GIP, and glucagon) works for weight loss, obesity, and metabolic health, and see key phase 2 clinical trial results on body‑weight reduction and cardiometabolic benefits.
Learn what marituglutide is, how its dual GLP-1/GIP “twincretin” mechanism works, and how it may outperform semaglutide for weight loss, glycemic control, and metabolic health in obesity and type 2 diabetes.
Discover how tirzepatide’s dual GIP/GLP-1 “twincretin” mechanism transforms type 2 diabetes treatment. Learn about its powerful HbA1c reduction, significant weight loss, cardiometabolic benefits, and once-weekly peptide design.
Learn what semaglutide is, how this GLP‑1 receptor agonist works in the pancreas, stomach, and brain, and why it’s transforming obesity, weight loss, and type 2 diabetes treatment with bariatric surgery–level results.
Discover how tirzepatide, a dual GIP and GLP‑1 receptor agonist, transforms type 2 diabetes treatment by enhancing glucose‑dependent insulin secretion, reducing glucagon, slowing gastric emptying, and promoting significant weight loss.
Learn why retatrutide (LY3437943), Eli Lilly’s next-generation triple-agonist targeting GLP-1, GIP, and glucagon receptors, is the most watched obesity drug candidate today, promising deeper, faster weight loss and improved metabolic health.
Learn how GLP‑1/GIP dual agonists like tirzepatide work at the molecular level to enhance insulin secretion, improve glucose control, and drive greater weight loss than GLP‑1 drugs alone. Explore mechanisms, incretin hormones, and key clinical trial results.
Discover how tirzepatide, a dual GIP/GLP‑1 receptor agonist, outperforms traditional GLP‑1 drugs for obesity and type 2 diabetes by enhancing insulin secretion, improving glucose control, and driving bariatric‑surgery‑level weight loss in clinical trials.
Learn how GLP‑1/GIP dual agonists work, their metabolic benefits, and why these next‑generation incretin peptide drugs are transforming treatment for obesity and type 2 diabetes with near‑surgical weight loss and powerful glucose control.